Eiken Chemical (4549) · InitiativeFirst stated

Development of a Companion Diagnostic System Using a Next-Generation Sequencer in Partnership with Illumina

First written in FY2022. . Latest entry: FY2022.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Expansion of the Molecular Pathology and Companion Diagnostic Development Support BusinessA theme 5 companies write about · 0 as a headwind · 5 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2022First statedAnnual report
「In fiscal 2021, we entered into an agreement with Illumina and began developing a companion diagnostic system using a next-generation sequencer.」
The Group disclosed for the first time the signing of an agreement with Illumina and the start of development of a companion diagnostic system using next-generation sequencers.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Eiken Chemical's next results are scheduled for 2026-10-29. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.